Intellectual Property India Publishes Patent Application for 'Receptor-Mediated Endocytosis For Targeted Degradation And Delivery Of Therapeutic Agents' Filed by Dana-Farber Cancer Institute, Inc.

MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517037427 A) filed by Dana-Farber Cancer Institute, Inc., Boston, on April 17, for 'receptor-mediated endocytosis for targeted degradation and delivery of therapeutic agents.'

Inventor(s) include Zhou, Xin; and Zhang, Dingpeng.

The application for the patent was published on June 13, under issue no. 24/2025.

According to the abstract released by the Intellectual Property India: "Disclosed are bispecific modulators that include a therapeutic agent. Embodiments include bispecific modulators conjugated to therapeutic agents. Bispecific modulators can bind to a protein of interest and to an internalizing receptor on a cell surface. Once bound, the protein of interest can be internalized and/or degraded inside a cell and can deliver the therapeutic agent to the cell."

The patent application was internationally filed on Sept. 20, 2023, under International application No.PCT/US2023/074693.

Disclaimer: Curated by HT Syndication.